Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 1 of 2: GR values. - Dataset (ID:20364)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell line | Drug name | Experimental replicate | Timepoint | Drug concentration | Live cell count | Average live cell count, DMSO control | Average live cell count (time = 0) | Log10(drug concentration) | GR value | Relative cell count (treatment versus DMSO) | Cell doublings (DMSO control) | Experiment name |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BT-20 | KIN001-244 | 3 | 72 | 0.001 | 3545.3 | 3578.0 | 586.9 | -3.0 | 0.993 | 0.991 | 2.608 | BT20 KIN001-244 0 3 |
| BT-20 | CAL-101 | 1 | 72 | 0.001 | 5598.0 | 6240.0 | 1443.3 | -3.0 | 0.900 | 0.897 | 2.112 | BT20 CAL101 0 1 |
| BT-549 | GDC-0980 | 1 | 72 | 0.001 | 5336.8 | 5343.8 | 1554.9 | -3.0 | 0.999 | 0.999 | 1.781 | BT549 GDC0980 0 1 72 |
| HCC70 | Buparlisib | 1 | 72 | 0.001 | 3514.0 | 3318.0 | 1279.8 | -3.0 | 1.090 | 1.060 | 1.374 | HCC70 BKM120 0 1 72 |
| HCC70 | BX-912 | 1 | 72 | 0.001 | 3458.3 | 3461.8 | 1279.8 | -3.0 | 0.999 | 0.999 | 1.436 | HCC70 BX912 0 1 72 |
| HCC70 | Pictilisib | 1 | 72 | 0.001 | 3315.0 | 3399.0 | 1279.8 | -3.0 | 0.965 | 0.975 | 1.409 | HCC70 GDC0941 0 1 72 |
| BT-20 | BX-912 | 2 | 72 | 0.001 | 2843.0 | 3312.0 | 1018.6 | -3.0 | 0.828 | 0.858 | 1.701 | BT20 BX912 0 2 |
| BT-549 | CAL-101 | 1 | 72 | 0.001 | 5321.8 | 5381.3 | 1554.9 | -3.0 | 0.988 | 0.989 | 1.791 | BT549 CAL101 0 1 72 |
| BT-20 | Omipalisib | 3 | 72 | 0.001 | 2990.5 | 3523.0 | 586.9 | -3.0 | 0.877 | 0.849 | 2.586 | BT20 GSK458 0 3 |
| BT-549 | Trametinib | 2 | 72 | 0.001 | 4676.8 | 4709.3 | 1249.6 | -3.0 | 0.993 | 0.993 | 1.914 | BT549 Trametinib 0 2 72 |
| BT-549 | WYE-125132 | 2 | 72 | 0.001 | 4564.5 | 4290.8 | 1249.6 | -3.0 | 1.070 | 1.060 | 1.780 | BT549 WYE125132 0 2 72 |
| BT-20 | ZSTK474 | 2 | 72 | 0.001 | 3212.8 | 3516.3 | 1018.6 | -3.0 | 0.902 | 0.914 | 1.787 | BT20 ZSTK474 0 2 |
| BT-20 | Sirolimus | 2 | 72 | 0.001 | 1740.0 | 3606.8 | 1018.6 | -3.0 | 0.341 | 0.482 | 1.824 | BT20 Rapamycin 0 2 |
| BT-549 | AS605240 | 3 | 72 | 0.001 | 4064.3 | 4082.5 | 1175.8 | -3.0 | 0.995 | 0.996 | 1.796 | BT549 AS605240 0 3 72 |
| BT-20 | Alpelisib | 2 | 72 | 0.001 | 2564.0 | 3290.8 | 1018.6 | -3.0 | 0.726 | 0.779 | 1.692 | BT20 BYL719 0 2 |
| BT-20 | PIK-93 | 1 | 72 | 0.001 | 5862.8 | 5875.8 | 1443.3 | -3.0 | 0.998 | 0.998 | 2.025 | BT20 PIK93 0 1 |
| BT-549 | Everolimus | 1 | 72 | 0.001 | 3638.5 | 5309.0 | 1554.9 | -3.0 | 0.616 | 0.685 | 1.772 | BT549 Everolimus 0 1 72 |
| HCC70 | Trametinib | 1 | 72 | 0.001 | 3041.3 | 3427.3 | 1279.8 | -3.0 | 0.839 | 0.887 | 1.421 | HCC70 Trametinib 0 1 72 |
| BT-20 | TGX221 | 2 | 72 | 0.001 | 2691.8 | 3211.0 | 1018.6 | -3.0 | 0.798 | 0.838 | 1.656 | BT20 TGX221 0 2 |
| BT-20 | AZD-6482 | 3 | 72 | 0.001 | 3256.8 | 3560.8 | 586.9 | -3.0 | 0.933 | 0.915 | 2.601 | BT20 AZD6482 0 3 |
| BT-549 | ZSTK474 | 2 | 72 | 0.001 | 4699.3 | 4867.8 | 1249.6 | -3.0 | 0.964 | 0.965 | 1.962 | BT549 ZSTK474 0 2 72 |
| BT-20 | AS605240 | 3 | 72 | 0.001 | 3319.5 | 3575.0 | 586.9 | -3.0 | 0.944 | 0.929 | 2.607 | BT20 AS605240 0 3 |
| BT-20 | CAL-101 | 2 | 72 | 0.001 | 3096.0 | 3469.3 | 1018.6 | -3.0 | 0.875 | 0.892 | 1.768 | BT20 CAL101 0 2 |
| HCC70 | Pictilisib | 2 | 72 | 0.001 | 2198.5 | 2487.3 | 722.8 | -3.0 | 0.866 | 0.884 | 1.783 | HCC70 GDC0941 0 2 72 |
| HCC70 | Everolimus | 2 | 72 | 0.001 | 1933.0 | 2397.8 | 722.8 | -3.0 | 0.766 | 0.806 | 1.730 | HCC70 Everolimus 0 2 72 |